The German Cannabis Market Report
Germany is the largest medical cannabis market in Europe, and June 2026 marks a defining moment in its trajectory. Following the implementation of the Medical Cannabis Act (MedCanG) on 1 April 2024, the market has undergone explosive structural expansion — with imports nearly tripling year-on-year, telemedicine driving unprecedented patient access, and a wave of regulatory tightening now poised to reshape competitive dynamics.
The German Cannabis Market Report 2026, produced by Prohibition Partners in partnership with Business of Cannabis, delivers a definitive data-led analysis of the country's medical cannabis landscape. Drawing on official BfArM import data, distributor and pharmacy intelligence, and proprietary market-sizing scenarios, this report equips operators, investors, regulators and advisors with the insights needed to navigate Europe's most important — and most contested — cannabis market.
From import flow analysis and Canada's market dominance, to dried flower SKU expansion, price compression, and the MedCanG amendment's implications, this report is the most comprehensive single resource on the German medical cannabis market available today. Includes scenario-based market sizing through 2030.
Lead author: Alex Khourdaji
Full Market Report and Data
£399
- 17-page professionally designed market intelligence report covering Germany's full medical cannabis landscape
- Latest BfArM import data through Q1 2026, including quarterly volumes, country-of-origin breakdowns, and revised quotas
- Scenario-based market sizing modelling four dispensing scenarios through 2030
- Dried flower SKU tracking from January 2025 to May 2026 — over 1,800 product lines analysed
- Pricing analysis across flowers, extracts and edibles, including premium and value tier dynamics
- Distributor portfolio rankings for 15 leading German market operators
- Regulatory deep-dive on the proposed MedCanG amendment and its impact on telemedicine, mail-order and prescriptions
- Canada vs Portugal supply chain analysis — uncovering the true effective share of imports
- Domestic cultivation outlook — Aphria/Tilray, Aurora, Demecan and the rise of German-grown product
- Patient access & telemedicine trajectory, including the 3,300%+ prescription surge
- Includes charts, tables, and benchmarks designed for boardroom and investor use
- Executive Summary (p.02)
- Market Overview (p.03)
- The MedCanG Reform
- Product Classification & Magistral Preparation
- Domestic Cultivation & Production
- Patient Access & Telemedicine
- Regulatory Tightening (MedCanG Amendment)
- Imports into Germany (p.05)
- Quarterly Import Volumes
- Canada's Dominance
- Annual Imports by Leading Country of Origin
- Products & Pricing (p.09)
- Product Format & Average Price Table
- Dried Flower
- Number of Dried Flower SKUs by Country of Origin
- Number of SKUs by Distributor Portfolio Size
- Market Sizing (p.14)
- Scenario-Based Market Sizing
- German Medical Cannabis Sales Volumes Forecast (2026–2030)
- Abbreviations & Acronyms (p.16)
The German Cannabis Market Report
Germany is the largest medical cannabis market in Europe, and June 2026 marks a defining moment in its trajectory. Following the implementation of the Medical Cannabis Act (MedCanG) on 1 April 2024, the market has undergone explosive structural expansion — with imports nearly tripling year-on-year, telemedicine driving unprecedented patient access, and a wave of regulatory tightening now poised to reshape competitive dynamics.
The German Cannabis Market Report 2026, produced by Prohibition Partners in partnership with Business of Cannabis, delivers a definitive data-led analysis of the country's medical cannabis landscape. Drawing on official BfArM import data, distributor and pharmacy intelligence, and proprietary market-sizing scenarios, this report equips operators, investors, regulators and advisors with the insights needed to navigate Europe's most important — and most contested — cannabis market.
From import flow analysis and Canada's market dominance, to dried flower SKU expansion, price compression, and the MedCanG amendment's implications, this report is the most comprehensive single resource on the German medical cannabis market available today. Includes scenario-based market sizing through 2030.
Lead author: Alex Khourdaji
- 17-page professionally designed market intelligence report covering Germany's full medical cannabis landscape
- Latest BfArM import data through Q1 2026, including quarterly volumes, country-of-origin breakdowns, and revised quotas
- Scenario-based market sizing modelling four dispensing scenarios through 2030
- Dried flower SKU tracking from January 2025 to May 2026 — over 1,800 product lines analysed
- Pricing analysis across flowers, extracts and edibles, including premium and value tier dynamics
- Distributor portfolio rankings for 15 leading German market operators
- Regulatory deep-dive on the proposed MedCanG amendment and its impact on telemedicine, mail-order and prescriptions
- Canada vs Portugal supply chain analysis — uncovering the true effective share of imports
- Domestic cultivation outlook — Aphria/Tilray, Aurora, Demecan and the rise of German-grown product
- Patient access & telemedicine trajectory, including the 3,300%+ prescription surge
- Includes charts, tables, and benchmarks designed for boardroom and investor use
As Trusted By
Insights
on the global cannabis industry
International Cannabis Weekly newsletter brings you the most important developments, news and informed commentary on the global cannabis industry. Join our community of 80,000+ subscribers.